Copyright © 2005 American Medical Association. All rights reserved.

Slides:



Advertisements
Similar presentations
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Advertisements

Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Renoprotective Effect of Renin-Angiotensin-Aldosterone.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risks of Progression of Retinopathy and Vision Loss.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Omeprazole for the Treatment of Symptomatic.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Influenza Vaccination and Cardiovascular.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reference Values for Self-recorded Blood Pressure:
Date of download: 6/28/2016 From: Effects of Blood Pressure Reduction in Mild Hypertension: A Systematic Review and Meta-analysis Ann Intern Med. 2015;162(3):
Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Antiarrhythmic Drugs for Maintaining Sinus Rhythm.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Application of the Screening for Heart Attack Prevention.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized Controlled Clinical Trial of the Serotonin.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2005 American Medical Association. All rights reserved.
The SPRINT Research Group
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2012 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:
Copyright © 2009 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.
Copyright © 2015 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2010 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2012 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
HOPE: Heart Outcomes Prevention Evaluation study
Copyright © 2012 American Medical Association. All rights reserved.
Ann Intern Med. 2009;150(11): doi: / Figure Legend:
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2001 American Medical Association. All rights reserved.
The Anglo Scandinavian Cardiac Outcomes Trial
Copyright © 2009 American Medical Association. All rights reserved.
Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.
Step Care Therapy for Hypertension in Diabetic Patients
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.
Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus  George L. Bakris, MD  Mayo Clinic.
Volume 81, Issue 7, Pages (April 2012)
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Presentation transcript:

Copyright © 2005 American Medical Association. All rights reserved. From: Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes MellitusResults of Prospectively Designed Overviews of Randomized Trials Arch Intern Med. 2005;165(12):1410-1419. doi:10.1001/archinte.165.12.1410 Figure Legend: Effects of angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists (CAs) vs placebo and more intensive vs less intensive blood pressure (BP)–lowering regimens (A) and of BP-lowering regimens based on different drug classes (B) on the risks of stroke, coronary heart disease, and heart failure. The P value by χ2 test of homogeneity (P homog) gives an indication of the constancy of effect in patients with and without diabetes mellitus. A P homog < .05 is taken to indicate that there is a difference in the effectiveness of the treatment regimen between patients with and without diabetes that is fairly unlikely to have occurred by chance alone. CI indicates confidence interval; D/BB, diuretic or β-blocker; RR, relative risk. Asterisk indicates that the overall mean BP difference (systolic/diastolic) during follow-up in the actively treated/first-listed group compared with the control/second-listed group, calculated by weighting the difference observed in each contributing trial by the number of individuals in the trial. Negative values indicate lower mean follow-up BP levels in first-listed treatment groups than in second-listed groups. Date of download: 10/19/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes MellitusResults of Prospectively Designed Overviews of Randomized Trials Arch Intern Med. 2005;165(12):1410-1419. doi:10.1001/archinte.165.12.1410 Figure Legend: Effects of angiotensin receptor blocker (ARB)–based regimens vs control regimens on the risks of major cardiovascular outcomes and death in individuals with and without diabetes mellitus. The P value by χ2 test of homogeneity (P homog) gives an indication of the constancy of effect in patients with and without diabetes. A P homog < .05 is taken to indicate that there is a difference in the effectiveness of the treatment regimen between patients with and without diabetes that is fairly unlikely to have occurred by chance alone. CI indicates confidence interval; RR, relative risk. Asterisk indicates that the overall mean blood pressure difference (systolic/diastolic) during follow-up in the ARB group vs the control group, calculated by weighting the difference observed in each contributing trial by the number of individuals in the trial. Negative values indicate lower mean follow-up blood pressure levels in the ARB group than in controls. Date of download: 10/19/2017 Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved. From: Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes MellitusResults of Prospectively Designed Overviews of Randomized Trials Arch Intern Med. 2005;165(12):1410-1419. doi:10.1001/archinte.165.12.1410 Figure Legend: Effects of angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists (CAs) vs placebo and more intensive vs less intensive bulood pressure (BP)–lowering regimens (A) and of BP-lowering regimens based on different drug classes (B) on the risks of major cardiovascular events, cardiovascular deaths, and total mortality. The P value by χ2 test of homogeneity (P homog) gives an indication of the constancy of effect in patients with and without diabetes mellitus. A P homog < .05 is taken to indicate that there is a difference in the effectiveness of the treatment regimen between patients with and without diabetes that is fairly unlikely to have occurred by chance alone. CI indicates confidence interval; D/BB, diuretic or β-blocker; RR, relative risk. Asterisk indicates that the overall mean BP difference (systolic/diastolic) during follow-up in the actively treated/first-listed group vs the control/second-listed group, calculated by weighting the difference observed in each contributing trial by the number of individuals in the trial. Negative values indicate lower mean follow-up BP levels in first-listed treatment groups than in second-listed groups. Date of download: 10/19/2017 Copyright © 2005 American Medical Association. All rights reserved.